Exelixis, Inc. (NASDAQ: EXEL) FY2025 revenue ~$2.40-2.55B (+10-17%) with adj. EPS ~$2.45-2.75 reflecting continued post-2024 ~$2.05-2.18B aggregate Cabometyx (cabozantinib) US net product revenue (~85%+ aggregate revenue mix; selected primary RCC + HCC + selected post-March 2025 NET indication launch) + selected continued post-2024 ~$300-360M aggregate Cabometyx + Cometriq royalties + selected various Other revenue (~14%+ aggregate revenue mix; selected various Ipsen + Takeda ex-US partner royalties) under continued President + CEO Michael Morrissey, PhD since June 2010 (~15-year tenure as Exelixis CEO). US specialty oncology biopharmaceutical company. Founded 1994 as Exelixis Pharmaceuticals in South San Francisco California (~31-year heritage); selected post-April 2000 NASDAQ IPO; selected post-November 2012 FDA approval (Cometriq); selected post-April 2016 FDA approval (Cabometyx for RCC); selected post-2018 FDA approval (Cabometyx for HCC); selected post-March 2025 FDA approval (Cabometyx for NET); selected post-June 2010 Michael Morrissey CEO appointment. Headquartered in Alameda California; ~1,300-1,500+ employees globally with ~$2.40-2.55B revenue. One primary business: specialty oncology biopharmaceutical (~100% ~$2.40-2.55B). Cabometyx franchise (RCC + HCC + NET): ~$2.05-2.18B Cabometyx US net product revenue; ~50,000-55,000 aggregate annual TRx; ~$15K-18K aggregate Net Sales/TRx; selected post-March 2025 NET indication launch; ~+10-15% aggregate Cabometyx growth. Zanzalintinib pipeline + post-2024 STELLAR readouts: zanzalintinib (XL092; next-gen TKI; 2L+ RCC + CRC + HNSCC); selected post-2024 Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 readouts; selected various AB6210 (next-gen ADC) + selected various pipeline. President + CEO Michael Morrissey, PhD since June 2010 (~15-year tenure); CFO Christopher Senner. Capital position: ~$0 dividend (no dividend track post-2000 NASDAQ IPO); ~$500-650M aggregate FY2024-2025 buyback program (~$300-400M aggregate FY2025); ~$1.5-1.8B aggregate cash + investments balance; net leverage ~negligible (~debt-free balance sheet); ~270-280M diluted shares. FY2026 thesis: Cabometyx franchise expansion (RCC + HCC + post-March 2025 NET launch) + Zanzalintinib pipeline (STELLAR-303 + STELLAR-304 + STELLAR-305 readouts) + ~$300-400M aggregate annual buybacks + ~$1.5-1.8B aggregate cash + selected potential post-2026 zanzalintinib launch. Risks: cabozantinib LOE (post-2030+ patent expiration), Pfizer Inlyta + Merck Lenvatinib + Eisai Lenvatinib competition, zanzalintinib Phase 3 readout binary failure, Cabometyx-to-zanzalintinib franchise transition slower-than-expected.

[EXEL] Exelixis Thesis 2026: Cabometyx Franchise Drives Zanzalintinib Pipeline

Key Takeaways

EXEL FY2025 revenue ~$2.40-2.55B (+10-17% YoY) with adj. EPS ~$2.45-2.75 reflecting continued post-2024 ~$2.05-2.18B aggregate Cabometyx (cabozantinib) US net product revenue (~85%+ aggregate revenue mix; selected primary RCC + HCC + selected post-March 2025 NET indication launch) + selected continued post-2024 ~$300-360M aggregate Cabometyx + Cometriq royalties + selected various Other revenue (~14%+ aggregate revenue mix; selected various Ipsen + Takeda ex-US partner royalties) under continued President + CEO Michael Morrissey, PhD since June 2010 (~15-year tenure as Exelixis CEO).
Cabometyx franchise (RCC + HCC + NET): ~$2.05-2.18B Cabometyx US net product revenue (~85%+ revenue mix); selected primary 1L + 2L Renal Cell Carcinoma (RCC) + selected post-2018 Hepatocellular Carcinoma (HCC) + selected post-March 2025 Neuroendocrine Tumor (NET; NCT04553016 CABINET pivotal); selected ~50,000-55,000 aggregate annual TRx + selected various ~$15K-18K aggregate Net Sales/TRx; selected various aggregate ~+10-15% aggregate Cabometyx growth.
Zanzalintinib pipeline + post-2024 STELLAR-303/304 readouts: zanzalintinib (XL092; next-gen TKI; 2L+ RCC + CRC + HNSCC) selected post-2024 Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 readouts; selected various AB6210 (next-gen ADC) + selected various pipeline; selected various aggregate Cabometyx-to-zanzalintinib franchise transition trajectory.
Capital position + balance sheet: ~$0 dividend (no dividend track post-2000 NASDAQ IPO); ~~$500-650M aggregate FY2024-2025 buyback program (~~$300-400M aggregate FY2025); aggregate capital return ~$300-400M FY2025; ~$1.5-1.8B aggregate cash + investments balance; net leverage ~negligible (selected ~debt-free balance sheet); ~270-280M diluted shares; non-investment grade Ba3/BB- credit rating (selected ~debt-free balance sheet but no public credit rating coverage).
FY2026 thesis catalysts: Cabometyx franchise expansion (RCC + HCC + post-March 2025 NET launch) + Zanzalintinib pipeline (STELLAR-303 + STELLAR-304 + STELLAR-305 readouts) + ~$300-400M aggregate annual buybacks + selected ~$1.5-1.8B aggregate cash + selected various potential post-2026 dividend initiation consideration + selected potential post-2026 zanzalintinib launch.

Company Background

Exelixis, Inc. (NASDAQ: EXEL) is a US specialty oncology biopharmaceutical company, founded 1994 as Exelixis Pharmaceuticals in South San Francisco California (~~31-year heritage; selected pioneer cabozantinib + small-molecule oncology). Selected post-April 2000 NASDAQ IPO (~~$120M aggregate IPO proceeds); selected post-2000-2025 selected various aggregate equity raises + selected various ~$1B+ aggregate cumulative R&D investment; selected post-2002 selected various Cabometyx (cabozantinib; oral tyrosine kinase inhibitor) discovery + clinical development; selected post-November 2012 FDA approval (Cometriq for medullary thyroid cancer); selected post-April 2016 FDA approval (Cabometyx for advanced RCC); selected post-2018 FDA approval (Cabometyx for advanced HCC); selected post-March 2025 FDA approval (Cabometyx for NET); selected post-June 2010 Michael Morrissey CEO appointment (selected continued post-2010 CEO); HQ Alameda California (selected post-2010 relocation from South San Francisco California); ~1,300-1,500+ employees globally.

EXEL operates 1 primary business: specialty oncology biopharmaceutical ~~100% revenue (~~$2.40-2.55B — selected primary Cabometyx US + selected various Cabometyx + Cometriq royalties from Ipsen + Takeda + selected various Other). Cabometyx US net product revenue ~~85%+ aggregate revenue mix (~~$2.05-2.18B; selected primary 1L + 2L RCC + selected post-2018 HCC + selected post-March 2025 NET) + Cabometyx + Cometriq royalties + selected various Other revenue ~~14%+ aggregate revenue mix (~~$300-360M; selected various Ipsen + Takeda ex-US partner royalties + selected various Co-Promotion). Geographic mix: US ~~95%+ revenue (~~$2.30-2.45B; selected primary Cabometyx US commercial) + International ~~5% (~~$110-120M; selected primary Ipsen + Takeda partner royalties).

Capital position: ~$0 dividend (no dividend track post-2000 NASDAQ IPO); ~~$500-650M aggregate FY2024-2025 buyback program (~~$300-400M aggregate FY2025); aggregate capital return ~$300-400M FY2025; ~$1.5-1.8B aggregate cash + investments balance; net leverage ~negligible (selected ~debt-free balance sheet); ~270-280M diluted shares.

Cabometyx Franchise (RCC + HCC + NET)

The Cabometyx franchise is EXEL's foundation thesis: ~$2.05-2.18B Cabometyx US net product revenue (~85%+ revenue mix) + selected primary 1L + 2L Renal Cell Carcinoma (RCC) + selected post-2018 Hepatocellular Carcinoma (HCC) + selected post-March 2025 Neuroendocrine Tumor (NET; NCT04553016 CABINET pivotal) + selected ~50,000-55,000 aggregate annual TRx + selected various ~$15K-18K aggregate Net Sales/TRx + selected various aggregate ~+10-15% aggregate Cabometyx growth. Selected primary EXEL Cabometyx franchise: post-April 2016 FDA approval RCC + post-2018 FDA approval HCC + post-March 2025 FDA approval NET + selected various post-2016-2025 selected various Cabometyx + checkpoint inhibitor (Opdivo + Tecentriq + selected various) combo IO regimens.

FY2025 Cabometyx dynamics ($2.05-2.18B aggregate Cabometyx US net product revenue): selected continued post-2024 ~50,000-55,000 aggregate annual TRx + ~$15K-18K aggregate Net Sales/TRx + selected post-March 2025 NET indication launch + selected various RCC + HCC + IO combo penetration + selected various ~+10-15% aggregate Cabometyx growth. Selected post-2024 ~$0.40-0.55 incremental annual EPS contribution as Cabometyx franchise expansion (RCC + HCC + post-March 2025 NET launch) drives incremental Cabometyx revenue + margin expansion.

FY2026 catalyst: continued Cabometyx franchise expansion + ~$0.40-0.55 incremental annual EPS contribution under continued President + CEO Michael Morrissey, PhD leadership (~15-year tenure). Selected aggregate ~$2.30-2.45B aggregate Cabometyx US net product revenue + selected various ~+12-18% aggregate Cabometyx growth + selected post-March 2025 NET launch trajectory + selected various RCC + HCC + IO combo penetration. Risks: cabozantinib LOE (selected post-2030+ aggregate composition-of-matter patent expiration; selected various aggregate Cabometyx-to-zanzalintinib franchise transition) + Pfizer Inlyta + Merck Lenvatinib (Lenvima) + Eisai Lenvatinib + selected various aggregate RCC + HCC + NET aggregate competitive displacement.

Zanzalintinib Pipeline + Post-2024 STELLAR Readouts

The zanzalintinib pipeline + post-2024 STELLAR readouts is EXEL's primary growth thesis: zanzalintinib (XL092; next-gen TKI; 2L+ RCC + CRC + HNSCC) + selected post-2024 Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 readouts + selected various AB6210 (next-gen ADC) + selected various pipeline + selected various aggregate Cabometyx-to-zanzalintinib franchise transition trajectory.

FY2025 zanzalintinib + pipeline dynamics: selected continued post-2024 zanzalintinib Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 enrollment + selected various AB6210 (next-gen ADC) + selected various pipeline development + selected various Cabometyx-to-zanzalintinib franchise transition planning. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution (selected continued post-2024 selected various R&D + clinical investment).

FY2026 catalyst: continued zanzalintinib STELLAR-303 + STELLAR-304 + STELLAR-305 Phase 3 readouts + ~$0.10-0.20 incremental EPS contribution. Selected aggregate STELLAR-303 (CRC) Phase 3 readout + selected various STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 readouts + selected various aggregate zanzalintinib FDA approval + selected various aggregate launch trajectory + selected various aggregate Cabometyx-to-zanzalintinib franchise transition. Risks: zanzalintinib STELLAR-303 + STELLAR-304 + STELLAR-305 Phase 3 readout binary failure (selected ~50-70% aggregate Phase 3 success rate base case) + Pfizer Inlyta + Merck Lenvatinib (Lenvima) + Eisai Lenvatinib + selected various global oncology + selected various aggregate competitive displacement + zanzalintinib launch slower-than-expected.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-2000 NASDAQ IPO) + ~~$500-650M aggregate FY2024-2025 buyback program (~~$300-400M aggregate FY2025) + aggregate capital return ~$300-400M FY2025 + ~$1.5-1.8B aggregate cash + investments balance + net leverage ~negligible (selected ~debt-free balance sheet) + ~270-280M diluted shares + non-investment grade Ba3/BB- credit rating (selected ~debt-free balance sheet but no public credit rating coverage).

FY2026 catalyst: continued ~$300-400M aggregate annual buybacks + selected continued ~$1.5-1.8B aggregate cash + selected various potential post-2026 dividend initiation consideration + selected potential post-2026 zanzalintinib launch + selected various M&A optionality.

Key Core Metrics

FY2025 revenue ~$2.40-2.55B (+10-17% YoY) vs $2.16B FY2024; adj. EPS ~$2.45-2.75
1 segment: Specialty Oncology Biopharmaceutical ~100% (Cabometyx US ~85%+ / royalties ~14%+ / Other ~1%)
Geographic mix: US ~95%+ + International ~5%
Cabometyx US: ~$2.05-2.18B revenue; ~50,000-55,000 aggregate annual TRx; ~$15K-18K Net Sales/TRx; selected post-March 2025 NET indication launch
Royalties + Other: ~$300-360M (selected primary Ipsen + Takeda partner royalties)
Pipeline: zanzalintinib (XL092) Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) + selected various AB6210 (next-gen ADC)
~$1.5-1.8B aggregate cash + investments balance
~270-280M diluted shares; ~$0 dividend (no dividend track post-2000 NASDAQ IPO)
~~$500-650M aggregate FY2024-2025 buyback program (~~$300-400M aggregate FY2025)
Net leverage ~negligible (~debt-free balance sheet)
President + CEO Michael Morrissey, PhD (since June 2010, ~15-year tenure); CFO Christopher Senner

Market Evaluation

EXEL trades as a specialty oncology biopharmaceutical company levered to Cabometyx franchise (RCC + HCC + post-March 2025 NET launch) + zanzalintinib pipeline (STELLAR-303 + STELLAR-304 + STELLAR-305 readouts) + ~debt-free balance sheet + ~$300-400M aggregate annual buybacks. Bull case: ~$2.05-2.18B Cabometyx + post-March 2025 NET launch + ~50,000-55,000 annual TRx + ~$15K-18K Net Sales/TRx + zanzalintinib STELLAR-303 + STELLAR-304 + STELLAR-305 Phase 3 readouts drive ~$2.85-3.20 adj. EPS FY2026 (+15-20% YoY). Bear case: cabozantinib LOE (selected post-2030+ aggregate composition-of-matter patent expiration) + Pfizer Inlyta + Merck Lenvatinib (Lenvima) + Eisai Lenvatinib competitive displacement + zanzalintinib STELLAR-303 + STELLAR-304 + STELLAR-305 Phase 3 readout binary failure + Cabometyx-to-zanzalintinib franchise transition slower-than-expected trigger material EPS compression. Base case: Cabometyx franchise expansion + zanzalintinib pipeline + ~debt-free balance sheet + ~$300-400M aggregate annual buybacks support continued ~$2.85-3.20 adj. EPS FY2026.

Cabometyx Franchise Drives Zanzalintinib Pipeline Deep Dive

Selected continued post-2024 ~$2.05-2.18B aggregate Cabometyx US net product revenue (~85%+ revenue mix; selected primary 1L + 2L RCC + selected post-2018 HCC + selected post-March 2025 NET) + selected continued post-2024 ~50,000-55,000 aggregate annual Cabometyx TRx + selected continued post-2024 ~$15K-18K aggregate Cabometyx Net Sales/TRx + selected continued post-2024 selected primary RCC + HCC + post-March 2025 NET indication launch + selected continued post-2024 ~$300-360M aggregate Cabometyx + Cometriq royalties from Ipsen + Takeda + selected various Other revenue + selected continued post-2024 selected various Cabometyx + checkpoint inhibitor (Opdivo + Tecentriq) combo IO regimens + selected continued post-2024 zanzalintinib (XL092; next-gen TKI; 2L+ RCC + CRC + HNSCC) + selected post-2024 Phase 3 STELLAR-303 (CRC) + STELLAR-304 (RCC) + STELLAR-305 (HNSCC) Phase 3 readouts + selected various AB6210 (next-gen ADC) + selected various pipeline + selected ~$1.5-1.8B aggregate cash + investments balance + selected ~debt-free balance sheet + selected ~$300-400M aggregate annual buybacks drive EXEL's primary FY2026 thesis. President + CEO Michael Morrissey, PhD (~15-year tenure) leadership continues post-June 2010 CEO appointment focus on Cabometyx franchise expansion + zanzalintinib pipeline + Cabometyx-to-zanzalintinib franchise transition + capital return discipline. Risks: cabozantinib LOE (selected post-2030+ aggregate composition-of-matter patent expiration) + Pfizer Inlyta + Merck Lenvatinib (Lenvima) + Eisai Lenvatinib + selected various global oncology + selected various aggregate RCC + HCC + NET aggregate competitive displacement + zanzalintinib STELLAR-303 + STELLAR-304 + STELLAR-305 Phase 3 readout binary failure (selected ~50-70% aggregate Phase 3 success rate base case) + zanzalintinib launch slower-than-expected + Cabometyx-to-zanzalintinib franchise transition slower-than-expected + selected aggregate Cabometyx franchise concentration considerations.